Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 21, 2012, Pages 8230-8235

  Karve, Shrirang ^a,b   Werner, Michael E ^a,b   Sukumar, Rohit ^a,b   Cummings, Natalie D ^a,b   Copp, Jonathan A ^a,b   Wang, Edina C ^a,b   Li, Chenxi ^c   Sethi, Manish ^a,b   Chen, Ronald C ^a   Pacold, Michael E ^d   Wang, Andrew Z ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Nanoparticle radiosensitizer; Nanotechnology

Indexed keywords

CISPLATIN; NANOCARRIER; PROTEIN KINASE; RADIOSENSITIZING AGENT; WORTMANNIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SYSTEMATIC REVIEW; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANDROSTADIENES; ANIMALS; CELL SURVIVAL; CHEMORADIOTHERAPY; DRUG DELIVERY SYSTEMS; HT29 CELLS; HUMANS; KB CELLS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NANOPARTICLES; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 84861442552     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1120508109     Document Type: Article

References (26)

1. Heath JR, Davis ME (2008) Nanotechnology and cancer. Annu Rev Med 59:251-265. (Pubitemid 351287936)
2. Wang AZ, Langer RS, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63(1):185-198.
3. Workman P, Clarke PA, Raynaud FI, van Montfort RL (2010) Drugging the PI3 kinome: From chemical tools to drugs in the clinic. Cancer Res 70(6):2146-2157.
4. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD (1997) Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3(7):1149-1156. (Pubitemid 27319761)
5. Hashimoto M, et al. (2003) DNA-PK: The major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway. J Radiat Res 44(2): 151-159. (Pubitemid 38738743)
6. Sarkaria JN, et al. (1998) Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58(19):4375-4382. (Pubitemid 28450040)
7. Yuan H, Luo J, Weissleder R, Cantley L, Josephson L (2006) Wortmannin-C20 conjugates generate wortmannin. J Med Chem 49(2):740-747. (Pubitemid 43157503)
8. Yuan H, Barnes KR, Weissleder R, Cantley L, Josephson L (2007) Covalent reactions of wortmannin under physiological conditions. Chem Biol 14(3):321-328. (Pubitemid 46428147)
9. Garcia-Echeverria C, Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27(41):5511-5526.
10. Yu K, et al. (2005) PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 4(5):538-545. (Pubitemid 41351227)
11. Zhu T, et al. (2006) Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. J Med Chem 49(4):1373-1378. (Pubitemid 43271889)
12. Howes AL, et al. (2007) The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 6(9):2505-2514. (Pubitemid 47480416)
13. Kong D, Yamori T (2008) Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy. Cancer Sci 99(9):1734-1740.
14. Zhang L, et al. (2008) Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 83(5):761-769. (Pubitemid 351556021)
15. Zhang L, et al. (2008) Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano 2(8):1696-1702.
16. Ihle NT, et al. (2004) Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3(7): 763-772. (Pubitemid 39193758)
17. Schultz RM, et al. (1995) In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 15(4):1135-1139.
18. Hall EJ (2000) Radiobiology for the Radiologist (Lippincott Williams & Wilkins, Philadelphia), 5th Ed, pp xi, 588 pp.
19. Ng SS, Tsao MS, Nicklee T, Hedley DW (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7(10): 3269-3275. (Pubitemid 32963853)
20. Lees-Miller SP, et al. (1995) Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 267(5201):1183-1185.
21. Gref R, et al. (1994) Biodegradable long-circulating polymeric nanospheres. Science 263(5153):1600-1603. (Pubitemid 24128361)
22. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. (Pubitemid 40349501)
23. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm: General principles. Nat Clin Pract Oncol 4(2):86-100. (Pubitemid 46189538)
24. Willett CG, Czito BG (2009) Chemoradiotherapy in gastrointestinal malignancies. Clin Oncol 21(7):543-556.
25. Eifel PJ (2006) Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol 16(3):177-185.
26. Chan DW, et al. (2002) Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 16(18):2333-2338. (Pubitemid 35034402)